AxoGen (AXGN) Misses Q1 EPS by 4c, provides guidance

AxoGen (NASDAQ: AXGN) reported Q1 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $41.4 million versus the consensus estimate of $41.96 million.

GUIDANCE:

AxoGen sees FY 2024 revenue of $177-181 million, versus the consensus of $179.3 million, which represents a growth rate of approximately 11% to 14%. We also reiterate our gross margin guidance for the full year to be in the range of 76% to 79%. Additionally, we expect to be net cashflow positive cumulatively for the period from April 1st through year end.

For earnings history and earnings-related data on AxoGen (AXGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c